Botanical species · safety record

Acorus gramineus

The EFSA Compendium of Botanicals holds 13 constituent measurements for Acorus gramineus. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Acorus gramineus Aiton

13Constituent measurements

0Safety records

4Cited sources

181Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 181 licensed products naming Acorus gramineus as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

Dry
fluid

Source material stated

Rhizome
Rhizome(s)
Root

What the records describe

Constituents measured

Plant parts

Preparations

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Asarone	Roots and other underground parts	Essential oil	≤ 1.43 Percent	GC-MS	Resolve DOI
Asarone	Roots and other underground parts	Essential oil	≥ 0.83 Percent	GC-MS	Resolve DOI
Asarone	Roots and other underground parts	Essential oil	≤ 1.97 Percent	GC-MS	Resolve DOI
Asarone	Roots and other underground parts	Essential oil	≥ 0.23 Percent	GC-MS	Resolve DOI
Beta-asarone	Roots and other underground parts	Essential oil	≤ 54.1 Percent	GC-MS	Resolve DOI
Beta-asarone	Roots and other underground parts	Essential oil	≥ 38.67 Percent	GC-MS	Resolve DOI
Beta-asarone	Roots and other underground parts	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Neolignans	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Quinones	Roots and other underground parts	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Beta-asarone	Roots and other underground parts	Essential oil	≥ 32.2 Percent	Unspecified	No resolvable identifier
Beta-asarone	Leaves	Essential oil	9 Percent	Unspecified	No resolvable identifier
Beta-asarone	Roots and other underground parts	Essential oil	≤ 62.38 Percent	Unspecified	No resolvable identifier
Methylisoeugenol	Roots and other underground parts	Essential oil	3.81 Percent	Unspecified	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Dai, Jian., Ha, Chengyong., Shen, Minmin. Systematic study of beta-asarone-rich volatile oil from Acori graminei rhizoma by off-line supercritical CO2 extraction-gas chromatography-mass spectrometry . Journal of separation science, 2008, vol. 31, no. 4, p. 714-720. DOI
Wang, Han-Zhang., Cheng, You-Gen., Fan, Cui-Sheng. Review of studies on chemical constituents and pharmacology of genus Acorus in China . Acta botanica yunnanica, 1998, vol. 0, no. SUPPL. 5, p. 96-100.
Lee, Seung Young., Moon, Eunjung., Kim, Sun Yeou., Choi, Sang Un., Lee, Kang Ro. Quinone Derivatives from the Rhizomes of Acorus gramineus and Their Biological Activities . Bioscience biotechnology and biochemistry, 2013, vol. 77, no. 2, p. 276-280. DOI
Park, Cheol Hyeong., Kim, Ki Hyun., Lee, Il Kyun., Lee, Seung Young., Choi, Sang Un., Lee, Jei Hyun., Lee, Kang Ro. Phenolic Constituents of Acorus gramineus. Archives of pharmacal research, 2011, vol. 34, no. 8, p. 1289-1296. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature